JP7605536B2 - エストロゲン受容体モジュレーター - Google Patents

エストロゲン受容体モジュレーター Download PDF

Info

Publication number
JP7605536B2
JP7605536B2 JP2023557230A JP2023557230A JP7605536B2 JP 7605536 B2 JP7605536 B2 JP 7605536B2 JP 2023557230 A JP2023557230 A JP 2023557230A JP 2023557230 A JP2023557230 A JP 2023557230A JP 7605536 B2 JP7605536 B2 JP 7605536B2
Authority
JP
Japan
Prior art keywords
methyl
trifluoroethyl
isoquinolin
tetrahydrooxazolo
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023557230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511044A (ja
Inventor
ヤン，シュエン
ジュ，チェンガン
チャン，チャオチュン
タリー，ジョン　ジェフリー
チェン，チャオラ
バオ，リミン
ミン，シャンヤン
シュ，リャンリャン
Original Assignee
深▲せん▼福沃薬業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深▲せん▼福沃薬業有限公司 filed Critical 深▲せん▼福沃薬業有限公司
Publication of JP2024511044A publication Critical patent/JP2024511044A/ja
Priority to JP2024212569A priority Critical patent/JP2025023300A/ja
Application granted granted Critical
Publication of JP7605536B2 publication Critical patent/JP7605536B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2023557230A 2021-03-15 2022-03-14 エストロゲン受容体モジュレーター Active JP7605536B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024212569A JP2025023300A (ja) 2021-03-15 2024-12-05 エストロゲン受容体モジュレーター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110277849.3 2021-03-15
CN202110277849 2021-03-15
PCT/CN2022/080680 WO2022194096A1 (zh) 2021-03-15 2022-03-14 雌激素受体调节剂

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024212569A Division JP2025023300A (ja) 2021-03-15 2024-12-05 エストロゲン受容体モジュレーター

Publications (2)

Publication Number Publication Date
JP2024511044A JP2024511044A (ja) 2024-03-12
JP7605536B2 true JP7605536B2 (ja) 2024-12-24

Family

ID=83246765

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023557230A Active JP7605536B2 (ja) 2021-03-15 2022-03-14 エストロゲン受容体モジュレーター
JP2024212569A Pending JP2025023300A (ja) 2021-03-15 2024-12-05 エストロゲン受容体モジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024212569A Pending JP2025023300A (ja) 2021-03-15 2024-12-05 エストロゲン受容体モジュレーター

Country Status (7)

Country Link
US (1) US20240217988A1 (https=)
EP (1) EP4310079A4 (https=)
JP (2) JP7605536B2 (https=)
KR (1) KR20230157439A (https=)
CN (2) CN115073493B (https=)
AU (1) AU2022240650B2 (https=)
WO (1) WO2022194096A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025023300A (ja) * 2021-03-15 2025-02-14 深▲せん▼福沃薬業有限公司 エストロゲン受容体モジュレーター

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017182493A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
JP2018521988A (ja) 2015-06-16 2018-08-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピペリジン誘導体およびその製造方法および医薬用途
JP2019510799A (ja) 2016-04-08 2019-04-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用
WO2019192533A1 (zh) 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
WO2019223715A1 (zh) 2018-05-23 2019-11-28 江苏恒瑞医药股份有限公司 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
WO2012142029A2 (en) * 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
CN104910137B (zh) * 2014-03-10 2017-04-19 山东轩竹医药科技有限公司 Cdk激酶抑制剂
WO2018138739A1 (en) * 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
WO2022194096A1 (zh) * 2021-03-15 2022-09-22 深圳福沃药业有限公司 雌激素受体调节剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521988A (ja) 2015-06-16 2018-08-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピペリジン誘導体およびその製造方法および医薬用途
JP2019510799A (ja) 2016-04-08 2019-04-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用
WO2017182493A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
WO2019192533A1 (zh) 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
WO2019223715A1 (zh) 2018-05-23 2019-11-28 江苏恒瑞医药股份有限公司 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025023300A (ja) * 2021-03-15 2025-02-14 深▲せん▼福沃薬業有限公司 エストロゲン受容体モジュレーター

Also Published As

Publication number Publication date
EP4310079A1 (en) 2024-01-24
AU2022240650A1 (en) 2023-10-19
AU2022240650B2 (en) 2025-01-30
US20240217988A1 (en) 2024-07-04
KR20230157439A (ko) 2023-11-16
CN115073493B (zh) 2024-12-10
JP2024511044A (ja) 2024-03-12
JP2025023300A (ja) 2025-02-14
WO2022194096A1 (zh) 2022-09-22
CN115073493A (zh) 2022-09-20
EP4310079A4 (en) 2024-10-30
CN119930646A (zh) 2025-05-06

Similar Documents

Publication Publication Date Title
JP7092784B2 (ja) αｖβ６インテグリン阻害剤
US10689377B2 (en) KRas G12C inhibitors
KR20240052795A (ko) Irak4 분해제 및 이의 제조방법과 응용
CN109496213B (zh) 螺环化合物及其制备和使用方法
IL262345A (en) Inhibitors of the kinase-like activin receptor
EP3617206A1 (en) Integrin inhibitors
CN114845711A (zh) Raf激酶的抑制剂
CN111065639A (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
JP2024519496A (ja) ブルトンのチロシンキナーゼの分解を標的化するための化合物
WO2025072451A1 (en) Ras-pi3k inhibitors for the treatment of cancer and immunological diseases
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
CN114805361B (zh) 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途
JP2022550641A (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
JP2025023300A (ja) エストロゲン受容体モジュレーター
TW202412784A (zh) 氮-喹唑啉化合物及使用方法
CN110655520A (zh) 嘧啶并环化合物及其制备方法和应用
CN113993861A (zh) 吡唑基-氨基-嘧啶基衍生物的苯醚和苯胺及其组合物和方法
CN118525021A (zh) 靶向malt1的蛋白降解化合物
CN116783188A (zh) 一种二氢异喹啉酮衍生物及其应用
JP2025131590A (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断剤としてのアリール複素環化合物
HK40106742A (en) Estrogen receptor antagonist
RU2824118C1 (ru) ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ ПИРАЗОЛ[1,5-a]ПИРИМИДИН-7-АМИНА, ЕГО КОМПОЗИЦИЯ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
TW202537962A (zh) 抑制α-V β-1整合素
WO2023220247A1 (en) Lrrk2 inhibitors
CN120957721A (zh) 抑制αvβ8整合素

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240604

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241205

R150 Certificate of patent or registration of utility model

Ref document number: 7605536

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150